|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Pleckstrin homology-like domain family A member 2 (PHLDA2) is located within the tumor suppressor region of 11p15, and its expression is suppressed in several malignant tumor types.
|
29861842 |
2018 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Here, we enriched T-ICs in OS cell lines and evaluated whether the imprinted gene TSSC3 (tumor-suppressing STF cDNA 3) associated with apoptosis could affect T-ICs in OS.
|
22610481 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Previously, we reported that tumor-suppressing STF cDNA 3 (TSSC3) functions as an imprinted tumor suppressor gene in osteosarcoma; however, the underlying mechanism by which TSSC3 suppresses the tumorigenesis and metastasis remain unclear.
|
30092789 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
IPL protein was absent in both of two cases of androgenetic complete hydatidiform mole examined by immunostaining, and IPL mRNA was absent in an additional three cases of this neoplasm examined by northern blotting.
|
13129680 |
2004 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Our previous study showed that TSSC3 acts as a tumor suppressor in osteosarcoma.
|
26265454 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
This is the first study to demonstrate that TSSC3 has a potent tumor suppressor role in osteosarcoma, probably by inhibition of growth and induction of apoptosis via the mitochondrial apoptosis pathway.
|
22021909 |
2012 |
|
Fetal Growth Retardation
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
These results further highlight a role for placental PHLDA2 in poor perinatal outcomes, specifically FGR associated with RFM.
|
26944942 |
2016 |
|
Fetal Growth Retardation
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In this series six imprinted genes were differentially expressed by ANOVA with a Benjamini-Hochberg false discovery rate of 0.05, with increased expression of PHLDA2 and decreased expression of MEST, MEG3, GATM, GNAS and PLAGL1 in IUGR placentae.
|
16125225 |
2006 |
|
Fetal Growth Retardation
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
When compared to age-matched appropriate for gestational age (AGA) infants, expression of PHLDA2 (p = 0.03) IGF2R (p < 0.05) was upregulated in IUGR infants.
|
22154689 |
2012 |
|
Fetal Growth Retardation
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Placental expression of PHLDA2 in selective intrauterine growth restriction in monozygotic twins.
|
24703004 |
2014 |
|
Fetal Growth Retardation
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Nine of the 52 (17%) expressed genes were significantly differentially expressed between normal and IUGR placentas; five were upregulated (PHLDA2, ILK2, NNAT, CCDC86, PEG10) and four downregulated (PLAGL1, DHCR24, ZNF331, CDKAL1).
|
19483473 |
2009 |
|
Fetal Growth Retardation
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that placental PHLDA2 may provide a biomarker for suboptimal skeletal growth in pregnancies uncomplicated by overt fetal growth restriction.
|
22100507 |
2012 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our laboratory has found genomic imprinting of a large genomic domain of human 11p15.5, identifying six imprinted genes within this domain: (a) insulin-like growth factor II (IGF-II), an important autocrine growth factor in a wide variety of malignancies; (b) H19, an untranslated RNA that is a putative growth suppressor gene regulating IGF-II; (c) p57KIP2, a cyclin-dependent kinase inhibitor that causes G1-S arrest; (d) KvLQT1, a voltage-gated potassium channel; (e) TSSC3, a gene that is homologous to mouse TDAG51, which is implicated in Fas-mediated apoptosis; and (f) TSSC5, a putative transmembrane protein-encoding gene.
|
10197590 |
1999 |
|
Malignant Neoplasms
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
These findings indicate that the TSSC3 gene is silenced through hypermethylation of the promoter regions, a mechanism commonly associated with gene silencing in cancer.
|
24268429 |
2014 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Moreover, knockdown of PHLDA2 expression inhibited cancer cell aggressiveness, suggesting PHLDA2 acted as an oncogene in PDAC cells.
|
29660218 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Loss of expression of TSSC3, an apoptosis-related imprinted gene, has been reported in several cases of malignant tumors.
|
22021909 |
2012 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
We have demonstrated that EZH2 plays a crucial role in tumor growth and distant metastasis in osteosarcoma; its oncogenic role is related to its regulation of the expression of TSSC3.
|
26265454 |
2015 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CCK-8, Edu, and clone formation assays; wound healing and Transwell assays; PCR; immunohistochemistry; immunofluorescence; and western blotting were used to investigated the responses in TSSC3-overexpressing osteosarcoma cell lines, and in xenografts and metastasis in vivo models, with or without autophagy deficiency caused by chloroquine or ATG5 silencing.
|
30092789 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In the clinical setting, expression of TSSC3, p-Src and Nanog is associated with recurrence, metastasis and surgical intervention.
|
29156746 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
TSSC3 expression (P=0.032, HR=0.405, 95%CI=0.177-0.926) and metastasis (P=0.010, HR=2.849, 95%CI=1.291-6.287) were considered to be independent prognostic factors in osteosarcoma.
|
27044808 |
2016 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
TSSC3 was expressed at a low level in T-ICs, while overexpression of TSSC3 could efficiently downregulate the expression of stem cell markers Nanog, Oct4 and Sox2 in T-ICs and decrease the clone formation rate, as well as downregulate tumorigenesis in MThFOB1.19 cells, supporting a suppressive role for TSSC3 in OS T-ICs.
|
22610481 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Previously, we reported that tumor-suppressing STF cDNA 3 (TSSC3) functions as an imprinted tumor suppressor gene in osteosarcoma; however, the underlying mechanism by which TSSC3 suppresses the tumorigenesis and metastasis remain unclear.
|
30092789 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Subcutaneous injection of TSSC3 overexpressing SaOS2 cells into athymic nude mice showed that TSSC3 also inhibited tumorigenesis through growth inhibition and apoptosis induction in vivo.
|
22021909 |
2012 |
|
Brain Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Of particular interest are: FGF9 which may stimulate the growth of prostate cancer, brain cancer and endometrium; and IER3 (IEX-1), PHLDA2 (TSS3), IAPP (amylin), and SST, all of which may play roles in apoptosis.
|
15691381 |
2005 |
|
Brain Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors.
|
10749982 |
2000 |